NASDAQ:TGTX 3 November 2025 - 11 January 2026

New York, January 9, 2026, 15:59 — Regular session TG Therapeutics shares fell about 7% on Friday, reversing an early rise and leaving the biotech near its session low. The stock was down 7% at $28.35 by 3:55 p.m. EST after opening at $30.69 and sliding as low as $28.215. It hit $30.83 earlier in the session.

TG Therapeutics, Inc. is a commercial-stage biopharmaceutical company specializing in treatments for B-cell mediated diseasesgurufocus.com. After years as a development-stage biotech, TG entered the commercial arena with Briumvi, its first approved product, and now generates the majority of revenue from Briumvi sales in the U.S.gurufocus.com. The company’s strategy centers on leveraging its expertise in B-cell biology to address both autoimmune disorders and B-cell cancers. Briumvi is TG’s flagship drug, approved by the FDA in December 2022 for adults with relapsing forms of multiple sclerosisir.tgtherapeutics.com. It is an intravenous anti-CD20 monoclonal antibody, similar in mechanism to Roche’s blockbuster Ocrevus, targeting B-cells to reduce MS disease activity. Briumvi’s Phase 3 trials showed robust efficacy in reducing relapses and MRI lesions in RMS. Notably, long-term extension data presented in late 2025 demonstrated that ~90% of Briumvi-treated patients remained free of disability progression after 6 yearsinvesting.com – an encouraging sign of sustained benefit.